Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
NCT05675683
·
clinicaltrials.gov ↗
COMPLETED
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
DRUG:
Capmatinib
Sponsor
Novartis Pharmaceuticals